Transaction · 0001835966-26-000008

Sandler Alan B.

Sandler Alan B., CDO, reported an open-market or private sale at Revolution Medicines, Inc. involving 1199.000000 shares for an estimated $244484.97. Reported holdings after the transaction were 52860.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCDO
RVMDRevolution Medicines, Inc.
Filing timeOct 01
Trade dateSep 29, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position traded2.22%Shares sold ÷ (holdings after + shares sold). Estimated position before: 54,059 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$205.89
Pre-filing
1mo ago +3.6%1w ago -6.3%1d ago -2.0%
Returns since
7d30d90d180d1y

RVMD price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
RVMD since 2026-10-01Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001835966-26-000008
Common Stock
Transaction date
Sep 29, 2026
Filed Oct 01, 2026, 10:00 PM · 2d delay
Shares
1.19k sh
$203.91 per share
Estimated value
-$244k
Computed from shares × price
Holdings after
52.8k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Development Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

  2. F2

    The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Perso…

  3. F3

    The transaction was executed in multiple trades at prices ranging from $201.41 to $202.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Perso…

  4. F4

    The transaction was executed in multiple trades at prices ranging from $202.42 to $203.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Perso…

  5. F5

    The transaction was executed in multiple trades at prices ranging from $203.42 to $204.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Perso…

  6. F6

    The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Perso…

  7. F7

    Includes 52,350 restricted stock units.

  8. F8

    Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from September 29, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) o…

Original filing · 0001835966-26-000008
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

RVMD